- Home
- SST vs CUE Comparison
SST vs CUE Comparison
Compare SST & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SST
- CUE
- Stock Information
- Founded
- SST 2013
- CUE 2014
- Country
- SST United States
- CUE United States
- Employees
- SST N/A
- CUE N/A
- Industry
- SST Diversified Commercial Services
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- SST Consumer Discretionary
- CUE Health Care
- Exchange
- SST Nasdaq
- CUE Nasdaq
- Market Cap
- SST 67.8M
- CUE 77.3M
- IPO Year
- SST N/A
- CUE 2018
- Fundamental
- Price
- SST $0.93
- CUE $1.15
- Analyst Decision
- SST Hold
- CUE Strong Buy
- Analyst Count
- SST 1
- CUE 5
- Target Price
- SST $2.00
- CUE $5.00
- AVG Volume (30 Days)
- SST 93.0K
- CUE 378.2K
- Earning Date
- SST 11-07-2024
- CUE 11-14-2024
- Dividend Yield
- SST N/A
- CUE N/A
- EPS Growth
- SST N/A
- CUE N/A
- EPS
- SST N/A
- CUE N/A
- Revenue
- SST $364,450,000.00
- CUE $9,532,000.00
- Revenue This Year
- SST N/A
- CUE $105.39
- Revenue Next Year
- SST $15.56
- CUE N/A
- P/E Ratio
- SST N/A
- CUE N/A
- Revenue Growth
- SST N/A
- CUE 149.53
- 52 Week Low
- SST $0.82
- CUE $0.45
- 52 Week High
- SST $3.02
- CUE $3.20
- Technical
- Relative Strength Index (RSI)
- SST 43.80
- CUE 45.52
- Support Level
- SST $0.82
- CUE $0.92
- Resistance Level
- SST $1.08
- CUE $1.09
- Average True Range (ATR)
- SST 0.08
- CUE 0.11
- MACD
- SST -0.00
- CUE 0.00
- Stochastic Oscillator
- SST 40.38
- CUE 45.71
About SST System1 Inc.
System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It serves customers in the areas of health and wellness, automotive, finance, travel, and entertainment. The company's segment includes Owned and Operated Advertising (O&O); and Partner Network. It generates maximum revenue from the Owned and Operated Advertising (O&O) segment.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.